News

Sep 17, 2025

Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders

➞

Sep 05, 2025

Mabwell Secures Pakistan's First Denosumab Injection Approval

➞

Sep 02, 2025

First-in-Human Study Results of Mabwell's Novel Anti-ST2 Monoclonal Antibody 9MW1911 Selected for ERS 2025 Presentation

➞

Sep 01, 2025

Mabwell Announces NMPA Acceptance of IND Application for Novel Anti-IL-11 mAb 9MW3811 in Pathological Scarring

➞

Aug 19, 2025

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA

➞

Aug 12, 2025

Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs

➞

Jul 31, 2025

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

➞

Jul 14, 2025

Mabwell Enters into License and Commercialization Agreement with UNILAB to Launch Denosumab Biosimilars in the Philippines

➞

Jul 01, 2025

Mabwell Passes Colombian GMP Inspection with “zero deficiencies” Result for Its Denosumab Injections

➞

Jun 27, 2025

Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection

➞